Zobrazeno 1 - 10
of 15
pro vyhledávání: '"V. Paul DiMondi"'
Autor:
Caroline Derrick, P. Brandon Bookstaver, Zhiqiang K. Lu, Christopher M. Bland, S. Travis King, Kayla R. Stover, Kathey Rumley, Shawn H. MacVane, Jenna Swindler, Scott Kincaid, Trisha Branan, David Cluck, Benjamin Britt, Kelly E. Pillinger, Bruce M. Jones, Virginia Fleming, V. Paul DiMondi, Sandy Estrada, Brad Crane, Brian Odle, Majdi N. Al-Hasan, Julie Ann Justo
Publikováno v:
Antibiotics, Vol 9, Iss 5, p 254 (2020)
Objectives: There is debate on whether the use of third-generation cephalosporins (3GC) increases the risk of clinical failure in bloodstream infections (BSIs) caused by chromosomally-mediated AmpC-producing Enterobacterales (CAE). This study evaluat
Externí odkaz:
https://doaj.org/article/f9f3f6fd996d4836b2e3f9a7e854a568
Autor:
Jenna Swindler, Kathey Fulton Rumley, Majdi N. Al-Hasan, V. Paul DiMondi, Shawn H. MacVane, Scott Kincaid, Kayla R. Stover, Virginia Fleming, Kelly E. Pillinger, Christopher M. Bland, Trisha Branan, P. Brandon Bookstaver, Brian Odle, Caroline Derrick, Zhiqiang K. Lu, S. Travis King, Sandy Estrada, David Cluck, Julie Ann Justo, Brad Crane, Bruce M Jones, Benjamin B Britt
Publikováno v:
Antibiotics
Antibiotics, Vol 9, Iss 254, p 254 (2020)
Volume 9
Issue 5
Antibiotics, Vol 9, Iss 254, p 254 (2020)
Volume 9
Issue 5
Objectives: There is debate on whether the use of third-generation cephalosporins (3GC) increases the risk of clinical failure in bloodstream infections (BSIs) caused by chromosomally-mediated AmpC-producing Enterobacterales (CAE). This study evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51232b4ffa55940f6cbe4afb766b2be5
http://europepmc.org/articles/PMC7277875
http://europepmc.org/articles/PMC7277875
Publikováno v:
Therapeutics and Clinical Risk Management
Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal infections continues to rise. Available antifungal agents to treat invasive fungal infections include polyenes, triazoles, and echinocandins. Unfortunately, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad4bb2b9a772a3da0a6670e6d5d72da6
https://doi.org/10.2147/tcrm.s90335
https://doi.org/10.2147/tcrm.s90335
Publikováno v:
International Journal of Clinical Pharmacy. 37:348-354
Background Invasive infections with Pseudomonas aeruginosa (PA) are associated with significant morbidity and mortality. While risk factors for mortality have been identified, their influence on short-term outcomes impacting treatment selection has n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d64d187daf3f524aba5c04ab63cb89ae
https://doi.org/10.1007/s11096-015-0067-6
https://doi.org/10.1007/s11096-015-0067-6
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 34:e120-e127
Antifungal catheter lock therapy (AfLT) with liposomal amphotericin B has been used in the treatment of pediatric central line infections caused by Candida species; however, reports describing the use of liposomal amphotericin B lock therapy in the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ba63793362b45fe7e571dc9b721799
https://doi.org/10.1002/phar.1433
https://doi.org/10.1002/phar.1433
Autor:
Richard H. Drew, V. Paul DiMondi
Publikováno v:
Current Fungal Infection Reports. 7:110-118
Invasive fungal infections result in significant morbidity and mortality, most notably in immunosuppressed patients. Aerosolized antifungal agents have been utilized primarily as prophylaxis (either alone or in combination with systemic antifungals)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01f633111a177ee02f1d712f6885b882
https://doi.org/10.1007/s12281-013-0137-y
https://doi.org/10.1007/s12281-013-0137-y
Autor:
Kelly D. Rafferty, V Paul DiMondi
Publikováno v:
Annals of Pharmacotherapy. 47:219-227
OBJECTIVE: To evaluate the efficacy and safety of administering vancomycin as a continuous infusion. DATA SOURCES: Literature was accessed through MEDLINE (1977-September 2012), Embase (1977-September 2012), and Google Scholar, using the terms vancom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662503f054d917976ec8e341285c98e0
https://doi.org/10.1345/aph.1r420
https://doi.org/10.1345/aph.1r420
Autor:
Christopher M. Bland, V. Paul DiMondi, Bruce M Jones, Majdi N. Al-Hasan, P. Brandon Bookstaver, Kayla R. Stover, Zhiqiang K. Lu, Virginia Fleming, S. Travis King, Caroline Derrick, Julie Ann Justo, David Cluck, Brian Odle, Trisha Branan, Sandy Estrada
Publikováno v:
Open Forum Infectious Diseases. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a931b8150a0f5844279dc49b0df9e31
https://doi.org/10.1093/ofid/ofv133.539
https://doi.org/10.1093/ofid/ofv133.539
Autor:
Timothy J. Bloom, V. Paul DiMondi
Publikováno v:
American Journal of Pharmaceutical Education. 81:6426
To the Editor: Based on many overheard conversations in the halls at the 2016 Annual Meeting of the American Association of Colleges of Pharmacy in Anaheim, many schools and colleges of pharmacy are undergoing or have recently undergone significant c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8595aec0060464ecf820adcac7551146
https://doi.org/10.5688/ajpe8176426
https://doi.org/10.5688/ajpe8176426
Publikováno v:
Infection and Drug Resistance
JNJ-Q2 is a novel, fifth-generation fluoroquinolone that has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942fd3df8afda74e48bf57beeb885011
https://doi.org/10.2147/idr.s105620
https://doi.org/10.2147/idr.s105620